The technology, which enables fully-automated cardiac safety analyses in cardiac intensive and QT studies, will be used at the contract research organisation’s (CRO) dedicated clinical research unit in Manhatten, New York.
The deal, financial terms of which were not disclosed, also includes a services agreement that will see NewCardio participate in the development of a new on-site electrocardiogram (ECG) analysis laboratory.
Clinilabs’ CEO, Gary Zammit, said: “We can now provide a differentiated and low cost solution for ECG data analysis to an industry that has been seeking a meaningful alternative to existing methods for some time.”
Vincent Renz, NewCardio’s COO was also upbeat about the partnership, explaining that it “is further evidence of the growing adoption of QTinno by innovative clinical trial service providers.”
“Our target customers are clinical trial service providers looking to deploy our proven technology to expand services and grow market opportunities. For Clinilabs, adding to its available scope of services by utilizing QTinno accomplished these two important goals.”
California-headquartered NewCardio, which has previously said its QTinno software is being used by a “Top 5 CRO,” expects growing regulatory pressure for early safety analysis will drive further demand for its technologies.
The firm explained that: “Screening for the risk of drug-induced adverse, often lethal, cardiovascular events – such as those identified with Vioxx, Seldane, and Avandia is of utmost importance for drug developers, and the public health in general.”
This, NewCardio went on to explain, can pose a problem for traditional ECG analysis during development which, for some studies, can involve the analysis of multiple ECG time points from one thousand or more patients.
“Using NewCardio’s 3-D approach, drug sponsors and CROs can automate this process, significantly reducing the cost and variability compared with non-automated methods, and reducing the time required to test new drugs in development.”